Day: February 9, 2022

VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to provide an update of recent activities and outlook for Q1 2022. The COVID-19 global pandemic continues to impact virtually all aspects of supply chain management, global trade, individual economies, and of course holds the attention of national and regional governments as priorities are identified and addressed. It is against this constantly evolving backdrop that Isracann has determined to continue to achieve strategic momentum against the eventual return to a normalized business environment. The appointment of Phil Floucault to the position of Chief Executive...

MONTREAL, Feb. 09, 2022 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). OPEN TO: Investors, analysts, and all interested parties   DATE:  Wednesday, March 9, 2022   TIME:  10:00 a.m. EST   CALL:   438-803-0545 (For all Montreal and overseas participants)  1-888-440-2194 (For all other North American participants)THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKETS OPEN THE DAY OF THE CONFERENCE CALL THROUGH GLOBENEWSWIRE. Please dial in 15 minutes before the conference begins. If you are unable to call in at this time, you may access a recording of the meeting by calling 1-800-770-2030 and entering the passcode 4899896 on your phone. This recording will be available on Wednesday, March 9, 2022 as of 1:30 p.m. until 11:59 p.m. on Wednesday, March 16, 2022. MEDIA WISHING TO QUOTE AN ANALYST SHOULD CONTACT...

LOWELL, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) — CSP Inc. (NASDAQ: CSPI), an award-winning provider of security and packet capture products, managed IT and professional services and technology solutions, reported improved financial and operating results for the fiscal 2022 first quarter ended December 31, 2021, and provided a business update. First Quarter Operating Highlights and Recent AchievementsTotal revenue increased 9% year over year and 24% compared to Q4 fiscal 2021 driven by higher services revenue Services revenue grew 22% compared to the year-ago first quarter Continued focus on higher margin products and services lead to overall gross margin of 29.2%“The business momentum we generated during fiscal 2021 Q4 propelled our fiscal 2022 Q1 performance,” commented Victor Dellovo, Chief Executive Officer. “We reported...

Scheduled for Friday, February 25, 2022 Jericho, NY, Feb. 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Paltalk, Inc. (Nasdaq: PALT) (“Paltalk,” the “Company,” “we,” “our” or “us”), a leading communications software innovator that powers multimedia social applications, is pleased to announce that it will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 25, 2022 at 11:30 AM EST. The conference will span three days, starting on February 23, 2022 and will run from 8:30 AM until 5:00 PM EST daily.  Paltalk’s presentation will be available by request to Aegis during the conference. The presentation will also be made available on Paltalk’s website at: https://investors.paltalk.com/events-and-presentations.  Paltalk Chairman and Chief Executive Officer Jason Katz will be presenting...

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16th at 5:00 p.m. Eastern Time. A live webcast of the presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company’s website for two weeks following the live presentation. About ChemoCentryxChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize...

SALT LAKE CITY, Feb. 09, 2022 (GLOBE NEWSWIRE) — Overstock.com, Inc. (NASDAQ:OSTK), a leading e-commerce home furnishings retailer, is scheduled to release fourth quarter and full year financial results for the period ended December 31, 2021, on Wednesday, February 23, 2022, before the market opens. The company has scheduled a conference call and webcast for 8:30am ET that day to discuss these results and take questions from participants during the live event. Questions may also be submitted to ir@overstock.com in advance. Webcast InformationTo access the live webcast and presentation slides, visit http://investors.overstock.com. To listen to the conference call via telephone, dial (877) 673-5346 and enter conference ID number 3659278 when prompted. Participants outside the U.S. or Canada who do not have internet access should...

Scalable kiosk design overcomes complex challenges VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) — UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to announce it is in advanced stage development of the “H3 Health Cube” as part of a growing lineup of new telehealth solutions designed for broad public deployment. UniDoc Health aims to innovate the health care sector by offering a complete Virtual Care Solution Model enabling remote doctor/patient engagement and multiple levels of care through modernization and utilization of new and innovative technologies. The key to UniDoc’s solution model is accessibility utilizing a variety of form factors best suited to location, environment, culture, and ability of the end user (patient). The solutions...

Securing ownership of the cultivation, manufacturing and retail facility supports the Company’s expansion plans in Massachusetts PHOENIX, Feb. 09, 2022 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, has signed a definitive agreement (the “Purchase Agreement”) to exercise its purchase option for ownership of its Taunton, Massachusetts facility for a purchase price of approximately $13 million. Operating since August 2018, the Company’s state-of-the-art Taunton facility, located at 30 Mozzone Boulevard, is comprised of a 100,000 square-foot building that includes cultivation, processing and a product manufacturing lab, as well...

MIAMI, Feb. 09, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, reaffirms its commitment to shareholders to launch its KetaDASH brand by completing the purchase of 100% of Rejuv IV. Rejuv IV provides mobile IV therapy in the San Francisco Bay Area, 7 days a week with flexible scheduling. Rejuv IV provides Ketamine treatments, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. Rejuv IV will become KetaDASH, a wholly owned subsidiary of Ehave, Inc. In addition to Ketamine treatments, Rejuv IV generates revenue by offering its clients and patients IV Drip Detox and Hangover Cures, IV Vitamin Therapy for Pain Management, IV Hydration Therapy for Health & Wellness, and...

License Provides Steep Hill California Lab with Greatly Expanded Service Offering LAS VEGAS, NV, Feb. 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Digipath, Inc. (OTCQB: DIGP) (“Digipath” or the “Company”), a service-oriented independent analytical testing laboratory, data analytics firm focused on the cannabis and hemp markets, is pleased to announce that it has obtained a compliance testing license from the State of California for the Steep Hill California cannabis and hemp testing laboratory operated by Digipath in Berkeley, CA. The license immediately allows the Steep Hill California lab to conduct compliance testing for all cannabis products, in addition to its existing R & D testing operations.  As previously announced, the Company signed a letter of intent to acquire a controlling interest in the Steep Hill...